Your account is not claimed yet. You can sign up with ORCID to claim your account.

Nour E A Abd El-Sattar (Nour El-Din Ahmed Abd El-Sattar)

ORCID

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 9

Top Venues

RSC advances

Pharmaceuticals (Basel, Switzerland)

ACS omega

This page only lists publications with an associated author ORCID identifier.

Publications

Mohamed Mohamady Ghobashy, Ghada Bassioni, Ahmed Zaher, H Abd El-Wahab, Norhan Nady, Amira El-Sayed, Amr Osman, Nour E A Abd El-Sattar
Radiation Synthesis of Carbon/Aluminum/Silica Aerogel Nanoporous Structure Derived from Polyacrylamide Hydrogel for High Temperature and Oil Removal Applications. ACS omega 8 (23) (2023)
Samia M Al-Muntaser, Ahmed Ali Al-Karmalawy, Abeer M El-Naggar, Ali Khalil Ali, Nour E A Abd El-Sattar, Eslam M Abbass
Novel 4-thiophenyl-pyrazole, pyridine, and pyrimidine derivatives as potential antitumor candidates targeting both EGFR and VEGFR-2; design, synthesis, biological evaluations, and in silico studies. RSC advances 13 (18) (2023)
Kurls E Anwer, Sanadelaslam S A El-Hddad, Nour E A Abd El-Sattar, Ahmed El-Morsy, Fathalla Khedr, Samy Mohamady, Doaa E Keshek, Samir A Salama, Khaled El-Adl, Noura S Hanafy
Five and six membered heterocyclic rings endowed with azobenzene as dual EGFR T790M and VEGFR-2 inhibitors: design, synthesis, in silico ADMET profile, molecular docking, dynamic simulation and anticancer evaluations. RSC advances 13 (50) (2023)
Samia M Al-Muntaser, Ahmed Ali Al-Karmalawy, Abeer M El-Naggar, Ali Khalil Ali, Nour E A Abd El-Sattar, Eslam M Abbass
Novel 4-thiophenyl-pyrazole, pyridine, and pyrimidine derivatives as potential antitumor candidates targeting both EGFR and VEGFR-2; design, synthesis, biological evaluations, and in silico studies. RSC advances 13 (18) (2023)
Samia M Al-Muntaser, Ahmed Ali Al-Karmalawy, Abeer M El-Naggar, Ali Khalil Ali, Nour E A Abd El-Sattar, Eslam M Abbass
Novel 4-thiophenyl-pyrazole, pyridine, and pyrimidine derivatives as potential antitumor candidates targeting both EGFR and VEGFR-2; design, synthesis, biological evaluations, and in silico studies. RSC advances 13 (18) (2023)
Samia M Al-Muntaser, Ahmed Ali Al-Karmalawy, Abeer M El-Naggar, Ali Khalil Ali, Nour E A Abd El-Sattar, Eslam M Abbass
Novel 4-thiophenyl-pyrazole, pyridine, and pyrimidine derivatives as potential antitumor candidates targeting both EGFR and VEGFR-2; design, synthesis, biological evaluations, and in silico studies. RSC advances 13 (18) (2023)
Kurls E Anwer, Nour E A Abd El-Sattar, Marium M Shamaa, Mohamed Y Zakaria, Botros Y Beshay
Design, Green Synthesis and Tailoring of Vitamin E TPGS Augmented Niosomal Nano-Carrier of Pyrazolopyrimidines as Potential Anti-Liver and Breast Cancer Agents with Accentuated Oral Bioavailability. Pharmaceuticals (Basel, Switzerland) 15 (3) (2022)
Mohamed Abdelwahab Abdelgawad, Khaled El-Adl, Sanadelaslam S A El-Hddad, Mostafa M Elhady, Nashwa M Saleh, Mohamed M Khalifa, Fathalla Khedr, Mohamed Alswah, AbdElAziz A Nayl, Mohammed M Ghoneim, Nour E A Abd El-Sattar
Design, Molecular Docking, Synthesis, Anticancer and Anti-Hyperglycemic Assessments of Thiazolidine-2,4-diones Bearing Sulfonylthiourea Moieties as Potent VEGFR-2 Inhibitors and PPARγ Agonists. Pharmaceuticals (Basel, Switzerland) 15 (2) (2022)
Nour E A Abd El-Sattar, Eman H K Badawy, Eman Z Elrazaz, Nasser S M Ismail
Discovery of pyrano[2,3- d ]pyrimidine-2,4-dione derivatives as novel PARP-1 inhibitors: design, synthesis and antitumor activity. RSC advances 11 (8) (2021)

Nour E A Abd El-Sattar.css-eqlu8i{font-size:small;padding-left:4px;} (Nour El-Din Ahmed Abd El-Sattar)

Publication Activity (10 Years)

Top Topics

Top Venues

Nour E A Abd El-Sattar (Nour El-Din Ahmed Abd El-Sattar)